In a report published Wednesday, BMO Capital Markets initiated coverage on Baxter International BAX with an Outperform rating and $70.00 price target.
BMO Capital noted, “We are initiating coverage of Baxter with an OUTPERFORM rating and a $70 price target. Baxter is an established and diversified global health care leader, generating 2011 sales of $13.9 billion (up 4.0% ex-fx) and operating two key divisions: BioScience (44% of 2011 revenue) and Medical Products (56% of revenue). It has one of the most robust pipelines of our coverage universe, and for the company, one of the most comprehensive in the last 25 years. Based on BAX's total return, long-term EPS growth plus dividend, we do not believe the current valuation reflects the company's return characteristics (lower P/E multiple, better return).”
Baxter International closed on Tuesday at $60.96.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in